3 not yet recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Afasci Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain AFA-281 - Lumbosacral Radiculopathy | Phase 2 | Not yet recruiting | Afasci Inc | 408 | 2027-04-01 | 2025-06-26 |
| A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder AFA-281 - Alcohol Abuse, Alcohol Abuse/addiction | Phase 2 | Not yet recruiting | Afasci Inc | 36 | 2025-10-01 | 2024-11-29 |
| A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers AFA-281 is a small molecule, orally available, Alcohol (Ethanol) - Alcohol, Alcohol Use Disorders | Phase 1 | Not yet recruiting | Afasci Inc | 20 | 2025-07-01 | 2024-12-06 |
| Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers AFA-281 - Pain, Neuropathic, Pain, Inflammatory | Phase 1 | Completed | Afasci Inc | 64 | 2023-04-11 | 2025-10-21 |
Alcoholism (2) · Neuralgia (2) · Anxiety Disorders (1) · Behavior, Addictive (1) · Depression (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Pain (1) · Peripheral Nervous System Diseases (1) · Sleep Wake Disorders (1)
Ethanol (1)
United States (2)
Xinmin Xie, MD, PhD (2) · Lara Ray, MD (1)